Proof that it can inhibit a previously intractable target in vivo enabled Forge Therapeutics Inc. to secure a $15 million A round to bring lead program FG-LpxC into the clinic. The molecule is a broad-spectrum Gram-negative antibiotic targeting the metalloenzyme LpxC.
